Terns Pharmaceuticals, Inc.

corporate_fare Company Profile

Terns Pharmaceuticals, Inc.

TERN·NASDAQ·Healthcare·CIK 0001831363

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule drug candidates for cancer and obesity. The company is developing TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in a Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a type of bone marrow cancer. Terns Pharmaceuticals also develops TERN-501, a thyroid hormone receptor beta agonist designed for improved metabolic stability and liver distribution. TERN-501 is in a Phase IIa clinical trial for metabolic dysfunction-associated steatohepatitis (MASH). Additionally, the company is working on the TERN-801 series, which are small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators intended for obesity. Terns Pharmaceuticals, Inc. was incorporated in 2016 and its headquarters are located in Foster City, California. As of May 4, 2026, Terns Pharmaceuticals, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is a publicly traded company in the Healthcare sector. Wiseek monitors TERN SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

Merck Completes Acquisition of Terns Pharmaceuticals; Shares to Delist (2026-05-05)
Merck Completes Acquisition of Terns Pharmaceuticals; Shares to Delist from Nasdaq (2026-05-05)
Merck Finalizes Acquisition of Terns Pharmaceuticals (2026-05-05)
Terns Pharmaceuticals Amends 10-K to Detail Executive Compensation and Equity Plans Amidst Tender Offer (2026-04-27)
FDA Grants Breakthrough Status to TERN-701 for Ph+ CML, Accelerating Development (2026-04-27)

Financial Snapshot

Fiscal year ended December 31, 2025

Net Income

-$96.21M

Diluted EPS

-$1.03

Op. Cash Flow

-$82.18M

Free Cash Flow

-$82.18M

Operating Income

-$110.12M

Cash & Equivalents

$524.75M

Debt / Equity

0.00×

Shares Outstanding

112.32M sh

Source: 10-K · filed 2026-04-27 · accession 0001193125-26-182140

Browse all tickers starting with T →

show_chartPrice Chart

Loading chart...

feed TERN - Latest Insights

Filing Type

Date Range

TERN

May 05, 2026, 9:21 AM EDT

Filing Type: 8-K

Importance Score:

Merck Completes Acquisition of Terns Pharmaceuticals; Shares to Delist

Price at Filing: $52.96

Real-time Price: $52.96

Change: $0 (0%)

Market Cap: $6.117B

Sentiment: Neutral

View Wiseek Article

TERN

May 05, 2026, 8:52 AM EDT

Filing Type: SC TO-T/A

Importance Score:

Merck Completes Acquisition of Terns Pharmaceuticals; Shares to Delist from Nasdaq

Price at Filing: $52.96

Real-time Price: $52.96

Change: $0 (0%)

Market Cap: $6.117B

Sentiment: Positive

View Wiseek Article

TERN

May 05, 2026, 8:45 AM EDT

Source: Dow Jones Newswires

Importance Score:

Merck Finalizes Acquisition of Terns Pharmaceuticals

Price at Filing: $52.96

Real-time Price: $52.96

Change: $0 (0%)

Market Cap: $6.117B

Sentiment: Positive

View Wiseek Article

TERN

Apr 27, 2026, 4:18 PM EDT

Filing Type: 10-K/A

Importance Score:

Terns Pharmaceuticals Amends 10-K to Detail Executive Compensation and Equity Plans Amidst Tender Offer

Price at Filing: $52.83

Real-time Price: $52.96

Change: +$0.130 (+0.25%)

Market Cap: $6.117B

Sentiment: Neutral

View Wiseek Article

TERN

Apr 27, 2026, 8:13 AM EDT

Source: Wiseek News

Importance Score:

FDA Grants Breakthrough Status to TERN-701 for Ph+ CML, Accelerating Development

Price at Filing: $52.86

Real-time Price: $52.96

Change: +$0.0961 (+0.18%)

Market Cap: $6.117B

Sentiment: Positive

View Wiseek Article

TERN

Apr 27, 2026, 8:10 AM EDT

Filing Type: 8-K

Importance Score:

TERN-701 Receives FDA Breakthrough Therapy Designation for CML, Accelerating Development Amidst Merck Acquisition

Price at Filing: $52.89

Real-time Price: $52.96

Change: +$0.0732 (+0.14%)

Market Cap: $6.117B

Sentiment: Positive

View Wiseek Article

TERN

Apr 24, 2026, 8:11 AM EDT

Filing Type: SC 14D9/A

Importance Score:

Merck Acquisition of Terns Pharmaceuticals Advances as HSR Waiting Period Expires; New Stockholder Lawsuit Disclosed

Price at Filing: $52.85

Real-time Price: $52.96

Change: +$0.110 (+0.21%)

Market Cap: $6.117B

Sentiment: Neutral

View Wiseek Article

TERN

Apr 24, 2026, 7:30 AM EDT

Filing Type: SC TO-T/A

Importance Score:

Merck Acquisition of Terns Pharmaceuticals Advances with HSR Waiting Period Expiration

Price at Filing: $52.87

Real-time Price: $52.96

Change: +$0.090 (+0.17%)

Market Cap: $6.117B

Sentiment: Neutral

View Wiseek Article

TERN

Apr 07, 2026, 7:44 AM EDT

Filing Type: SC 14D9

Importance Score:

Terns Board Unanimously Recommends Shareholders Accept Merck's $53.00/Share Cash Tender Offer

Price at Filing: $52.70

Real-time Price: $52.96

Change: +$0.260 (+0.49%)

Market Cap: $6.117B

Sentiment: Positive

View Wiseek Article

TERN

Apr 07, 2026, 7:00 AM EDT

Filing Type: SC TO-T

Importance Score:

Merck Commences Tender Offer to Acquire Terns Pharmaceuticals for $53.00 Per Share in Cash

Price at Filing: $52.70

Real-time Price: $52.96

Change: +$0.260 (+0.49%)

Market Cap: $6.117B

Sentiment: Positive

View Wiseek Article

TERN

Mar 25, 2026, 7:17 AM EDT

Filing Type: 8-K

Importance Score:

Merck to Acquire Terns Pharmaceuticals for $53.00/Share, Valuing Company at $6.7 Billion

Price at Filing: $52.56

Real-time Price: $52.96

Change: +$0.400 (+0.76%)

Market Cap: $6.117B

Sentiment: Positive

View Wiseek Article

TERN

Mar 25, 2026, 6:48 AM EDT

Source: Dow Jones Newswires

Importance Score:

Merck to Acquire Terns Pharmaceuticals, Bolstering Hematology Pipeline with CML Drug TERN-701

Price at Filing: $52.62

Real-time Price: $52.96

Change: +$0.340 (+0.65%)

Market Cap: $6.117B

Sentiment: Positive

View Wiseek Article

TERN

Jan 22, 2026, 4:07 PM EST

Filing Type: 8-K

Importance Score:

Terns Pharmaceuticals Secures Exclusive Worldwide Rights to TERN-701 Patents from Hansoh

Price at Filing: $36.13

Real-time Price: $52.96

Change: +$16.83 (+47%)

Market Cap: $6.117B

Sentiment: Positive

View Wiseek Article

TERN

Jan 09, 2026, 4:05 PM EST

Filing Type: 8-K

Importance Score:

Terns Pharmaceuticals Secures $1B Cash Runway into 2031, Advances Lead Oncology Drug TERN-701 with Fast Track and Positive Data

Price at Filing: $35.48

Real-time Price: $52.96

Change: +$17.48 (+49%)

Market Cap: $6.117B

Sentiment: Positive

View Wiseek Article

TERN

Jan 06, 2026, 8:26 PM EST

Filing Type: 4

Importance Score:

Terns Pharmaceuticals CEO Exercises Options and Increases Stake by Over $3.2M Net

Price at Filing: $39.30

Real-time Price: $52.96

Change: +$13.66 (+35%)

Market Cap: $6.117B

Sentiment: Positive

View Wiseek Article

corporate_fare Company Profile